Raymond James & Associates Purchases 6,293 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Raymond James & Associates increased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 13.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 53,611 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,293 shares during the period. Raymond James & Associates’ holdings in Jazz Pharmaceuticals were worth $5,973,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of JAZZ. Versant Capital Management Inc lifted its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the second quarter valued at $29,000. EverSource Wealth Advisors LLC increased its position in Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the period. Finally, Gladius Capital Management LP bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth $33,000. Institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Wells Fargo & Company cut their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Morgan Stanley lowered their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Friday, July 12th. Finally, Piper Sandler lowered their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $173.43.

Jazz Pharmaceuticals Stock Down 2.8 %

Shares of JAZZ opened at $110.03 on Friday. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.48. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The stock has a fifty day simple moving average of $110.84 and a two-hundred day simple moving average of $109.56. The company has a market capitalization of $6.79 billion, a PE ratio of 18.96, a price-to-earnings-growth ratio of 1.41 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating the consensus estimate of $3.80 by $0.87. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. As a group, equities analysts forecast that Jazz Pharmaceuticals plc will post 16.06 EPS for the current year.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.